ArticleEuropean archives of psychiatry and clinical neuroscience2012
The lifetime and past-year prevalence of dual diagnosis in people with schizophrenia across Europe: findings from the European Schizophrenia Cohort (EuroSC).
Article in European archives of psychiatry and clinical neuroscience, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 70 citations in OpenAlex.
- Effects of nicotine on social cognition, social competence and self-reported stress in schizophrenia patients and healthy controls.European archives of psychiatry and clinical neuroscience · 2013Trial
- Smoking prevalence and correlates among inpatients with schizophrenia or schizoaffective disorder.Scientific reports · 2025Article
- Management of schizophrenia and comorbid substance use disorders: expert review and guidance.Annals of general psychiatry · 2024Review
- Influence of cannabis use on incidence of psychosis in people at clinical high risk.Psychiatry and clinical neurosciences · 2023Article
- Association Study of OPRM1 Gene in a Sample of Schizophrenia Patients With Alcohol Dependence or Abuse.The Canadian journal of addiction · 2019Article
- Factors Affecting the Management of Somatic Comorbidity in Tunisian Patients with Schizophrenia.The Psychiatric quarterly · 2019Article
- Comorbid opioid use is undertreated among forensic patients with schizophrenia.Substance abuse treatment, prevention, and policy · 2018Article
- A prospective hospital study of alcohol use disorders, comorbid psychiatric conditions and withdrawal prognosis.Annals of general psychiatry · 2016Article
- Bridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practice.Neuropsychiatric disease and treatment · 2015Review
- Employment and the associated impact on quality of life in people diagnosed with schizophrenia.Neuropsychiatric disease and treatment · 2015Review
- The prevalence of metabolic syndrome in people with severe mental illness: a mediation analysis.Social psychiatry and psychiatric epidemiology · 2014Article
- Do patient and ward-related characteristics influence the use of coercive measures? Results from the EUNOMIA international study.Social psychiatry and psychiatric epidemiology · 2014Article
- Prevalence and correlates of binge drinking among young adults using alcohol: a cross-sectional survey.BioMed research international · 2014Article
- Impact of substance use disorder on presentation and short-term course of schizophrenia.Psychiatry journal · 2014Article
- A further evaluation of decision-making under risk and under ambiguity in schizophrenia.European archives of psychiatry and clinical neuroscience · 2013Article
- Depression after stroke and risk of mortality: a systematic review and meta-analysis.Stroke research and treatment · 2013Article
- Association between schizophrenia and urinary calculi: a population-based case-control study.PloS one · 2013Article
- Schizophrenia: from risk genes to outcome and comorbidity.European archives of psychiatry and clinical neuroscience · 2012Article
- Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States.International journal of methods in psychiatric research · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Relatively little is known about rates of comorbid drug and alcohol problems in people with schizophrenia outside the USA. Most studies have recruited from single countries. Newly available data provided an unmatched opportunity to investigate the prevalence of comorbid dependence on alcohol and other psychoactive substances in people with schizophrenia in France, Germany and the UK at the same time. The European Schizophrenia Cohort study data set used semi-structured clinical interviews to establish DSM-IV diagnoses. 1,208 patients were interviewed in nine centres. The lifetime rate for comorbid dependence on any substance was highest in the UK (35 %), but considerably lower in Germany (21 %) and in France (19 %), and generally more than double the past-year rates. Dependence on alcohol and on other psychoactive substances showed similar variations (comorbid alcohol dependence: UK 26 %; Germany 18 %; France 14 %; comorbid drug dependence: UK 18 %; Germany 8 %; France 7 %). Differences within countries persisted after controlling for individual characteristics. The relative odds of dependence were higher than in the general population, but varied between countries and centres. Dependence disorders are a common problem in people with schizophrenia in Western Europe, although effective service configurations have yet to be developed. Overall, these European rates are less than those reported from the USA. Research comparing people with current comorbidity with those who are no longer dependent is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.